Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vildagliptin Oral Antidiabetic Agent – For The Treatment of Type 2 Diabetes

Drug (Brand / Generic)

Galvus (vildagliptin)

Company / Licensee

Novartis

Therapy Class

DPP-IV inhibitor

Product Description

Inhibits action of DPP-IV, so delaying degradation of GLP-1

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved Europe; pre-registration US
Expand

Go Top